Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from its Phase 2 clinical study of sotagliflozin in type 1 diabetes will be presented in oral and poster presentations at the European Association for the Study of Diabetes, which will be held September 14–18 in Stockholm, Sweden.
Currently in Phase 3 clinical development for the treatment of type 1 diabetes, sotagliflozin is the first investigational therapy to target both SGLT1 and SGLT2, key proteins that transport glucose in the body.
The oral presentation, entitled “Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, improves glycaemic control in type 1 diabetes mellitus in a randomised, placebo-controlled, double-blind study,” will be presented at 3:45 p.m., September 17, by John B. Buse, M.D., Ph.D., Professor of Medicine and Chief of the Division of Endocrinology at the University of North Carolina, Chapel Hill.
The poster, entitled “Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduces glucose variability in type 1 diabetes mellitus in a randomised, placebo-controlled, double-blind study,” will be presented at 2:15 p.m., September 17, by Paul Strumph, M.D., Lexicon’s Vice President of Clinical Development and the development lead for sotagliflozin.
Discovered using Lexicon’s unique approach to gene science, sotagliflozin is a first-in-class dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin has been shown in a Phase 2 study to improve glycemic control in people with type 1 diabetes while reducing their need for mealtime insulin. Lexicon is conducting Phase 3 clinical trials of sotagliflozin and retains full worldwide rights to market the compound.
Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science, based on Nobel Prize-winning technology, to discover and develop precise medicines for patients with serious, chronic conditions. Through its Genome5000™ program, Lexicon scientists have studied the role and function of nearly 5,000 genes over the last 20 years and have identified more than 100 protein targets with therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has a pipeline of promising drug candidates in clinical and pre-clinical development in oncology, diabetes and metabolism. For additional information please visit www.lexpharma.com.